Coherus BioSciences Competitors

Coherus BioSciences (NASDAQ:CHRS) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Valuation & Earnings

This table compares Coherus BioSciences and Beam Therapeutics' gross revenue, earnings per share and valuation.

Coherus BioSciences has higher revenue and earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Coherus BioSciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and price targets for Coherus BioSciences and Beam Therapeutics, as provided by MarketBeat.

Coherus BioSciences presently has a consensus price target of $26.50, indicating a potential upside of 67.40%. Beam Therapeutics has a consensus price target of $96.00, indicating a potential upside of 32.23%. Given Coherus BioSciences' stronger consensus rating and higher possible upside, research analysts clearly believe Coherus BioSciences is more favorable than Beam Therapeutics.

Institutional and Insider Ownership

49.8% of Beam Therapeutics shares are owned by institutional investors. 15.9% of Coherus BioSciences shares are owned by company insiders. Comparatively, 0.7% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Coherus BioSciences and Beam Therapeutics' net margins, return on equity and return on assets.

Summary

Coherus BioSciences beats Beam Therapeutics on 11 of the 13 factors compared between the two stocks.

SpringWorks Therapeutics (NASDAQ:SWTX) and Coherus BioSciences (NASDAQ:CHRS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Risk & Volatility

SpringWorks Therapeutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. Comparatively, Coherus BioSciences has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500.

Earnings & Valuation

This table compares SpringWorks Therapeutics and Coherus BioSciences' revenue, earnings per share and valuation.

Coherus BioSciences has higher revenue and earnings than SpringWorks Therapeutics. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Coherus BioSciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for SpringWorks Therapeutics and Coherus BioSciences, as reported by MarketBeat.com.

SpringWorks Therapeutics presently has a consensus target price of $91.00, indicating a potential upside of 22.31%. Coherus BioSciences has a consensus target price of $26.50, indicating a potential upside of 67.40%. Given Coherus BioSciences' higher possible upside, analysts plainly believe Coherus BioSciences is more favorable than SpringWorks Therapeutics.

Profitability

This table compares SpringWorks Therapeutics and Coherus BioSciences' net margins, return on equity and return on assets.

Institutional and Insider Ownership

76.3% of SpringWorks Therapeutics shares are owned by institutional investors. 51.2% of SpringWorks Therapeutics shares are owned by company insiders. Comparatively, 15.9% of Coherus BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Coherus BioSciences beats SpringWorks Therapeutics on 10 of the 13 factors compared between the two stocks.

Relay Therapeutics (NASDAQ:RLAY) and Coherus BioSciences (NASDAQ:CHRS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Relay Therapeutics and Coherus BioSciences, as reported by MarketBeat.com.

Relay Therapeutics currently has a consensus price target of $57.40, indicating a potential upside of 53.52%. Coherus BioSciences has a consensus price target of $26.50, indicating a potential upside of 67.40%. Given Coherus BioSciences' higher probable upside, analysts plainly believe Coherus BioSciences is more favorable than Relay Therapeutics.

Earnings & Valuation

This table compares Relay Therapeutics and Coherus BioSciences' top-line revenue, earnings per share and valuation.

Coherus BioSciences has higher revenue and earnings than Relay Therapeutics.

Profitability

This table compares Relay Therapeutics and Coherus BioSciences' net margins, return on equity and return on assets.

Insider and Institutional Ownership

98.4% of Relay Therapeutics shares are owned by institutional investors. 15.9% of Coherus BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Coherus BioSciences beats Relay Therapeutics on 6 of the 9 factors compared between the two stocks.

Revolution Medicines (NASDAQ:RVMD) and Coherus BioSciences (NASDAQ:CHRS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

Analyst Ratings

This is a breakdown of current ratings and target prices for Revolution Medicines and Coherus BioSciences, as provided by MarketBeat.

Revolution Medicines currently has a consensus price target of $50.75, suggesting a potential upside of 11.54%. Coherus BioSciences has a consensus price target of $26.50, suggesting a potential upside of 67.40%. Given Coherus BioSciences' higher possible upside, analysts clearly believe Coherus BioSciences is more favorable than Revolution Medicines.

Profitability

This table compares Revolution Medicines and Coherus BioSciences' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Revolution Medicines and Coherus BioSciences' revenue, earnings per share (EPS) and valuation.

Coherus BioSciences has higher revenue and earnings than Revolution Medicines.

Insider & Institutional Ownership

85.8% of Revolution Medicines shares are held by institutional investors. 15.9% of Coherus BioSciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Coherus BioSciences beats Revolution Medicines on 7 of the 9 factors compared between the two stocks.

Coherus BioSciences (NASDAQ:CHRS) and NantKwest (NASDAQ:NK) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, analyst recommendations and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Coherus BioSciences and NantKwest, as reported by MarketBeat.

Coherus BioSciences currently has a consensus target price of $26.50, suggesting a potential upside of 67.40%. NantKwest has a consensus target price of $18.00, suggesting a potential downside of 32.84%. Given Coherus BioSciences' higher possible upside, equities research analysts clearly believe Coherus BioSciences is more favorable than NantKwest.

Profitability

This table compares Coherus BioSciences and NantKwest's net margins, return on equity and return on assets.

Volatility and Risk

Coherus BioSciences has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500. Comparatively, NantKwest has a beta of 2.61, indicating that its share price is 161% more volatile than the S&P 500.

Valuation and Earnings

This table compares Coherus BioSciences and NantKwest's revenue, earnings per share and valuation.

Coherus BioSciences has higher revenue and earnings than NantKwest. NantKwest is trading at a lower price-to-earnings ratio than Coherus BioSciences, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

9.4% of NantKwest shares are held by institutional investors. 15.9% of Coherus BioSciences shares are held by company insiders. Comparatively, 71.7% of NantKwest shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Coherus BioSciences beats NantKwest on 9 of the 14 factors compared between the two stocks.

Coherus BioSciences (NASDAQ:CHRS) and Editas Medicine (NASDAQ:EDIT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, analyst recommendations and valuation.

Institutional & Insider Ownership

87.5% of Editas Medicine shares are held by institutional investors. 15.9% of Coherus BioSciences shares are held by company insiders. Comparatively, 0.9% of Editas Medicine shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Coherus BioSciences and Editas Medicine's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Coherus BioSciences and Editas Medicine, as reported by MarketBeat.

Coherus BioSciences currently has a consensus target price of $26.50, suggesting a potential upside of 67.40%. Editas Medicine has a consensus target price of $49.2222, suggesting a potential upside of 18.24%. Given Coherus BioSciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Coherus BioSciences is more favorable than Editas Medicine.

Volatility and Risk

Coherus BioSciences has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 2.1, indicating that its share price is 110% more volatile than the S&P 500.

Valuation and Earnings

This table compares Coherus BioSciences and Editas Medicine's revenue, earnings per share and valuation.

Coherus BioSciences has higher revenue and earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than Coherus BioSciences, indicating that it is currently the more affordable of the two stocks.

Summary

Coherus BioSciences beats Editas Medicine on 11 of the 14 factors compared between the two stocks.